User login
Pathways, processes, team work: paving the way for value-based care with the quadruple aim
While we can imagine what a high-quality, state-of- the-art cancer care system might deliver in terms of value-based care and how it might yield exceptional patient outcomes and job satisfaction for our staff, most of us are struggling with the processes and tools needed to achieve defined outcomes that can be benchmarked and further refined – all within the limits of our already hectic 12-, 14,- 16+-hour days. As more community practices, academic centers, and hospitals align to share and leverage expertise in their efforts to form more streamlined, patient-centered delivery systems for cancer care, we need to set up, refine, and integrate pathways into pathway programs that will pave the way to the delivery of value-based care.
Click on the PDF icon at the top of this introduction to read the full article.
While we can imagine what a high-quality, state-of- the-art cancer care system might deliver in terms of value-based care and how it might yield exceptional patient outcomes and job satisfaction for our staff, most of us are struggling with the processes and tools needed to achieve defined outcomes that can be benchmarked and further refined – all within the limits of our already hectic 12-, 14,- 16+-hour days. As more community practices, academic centers, and hospitals align to share and leverage expertise in their efforts to form more streamlined, patient-centered delivery systems for cancer care, we need to set up, refine, and integrate pathways into pathway programs that will pave the way to the delivery of value-based care.
Click on the PDF icon at the top of this introduction to read the full article.
While we can imagine what a high-quality, state-of- the-art cancer care system might deliver in terms of value-based care and how it might yield exceptional patient outcomes and job satisfaction for our staff, most of us are struggling with the processes and tools needed to achieve defined outcomes that can be benchmarked and further refined – all within the limits of our already hectic 12-, 14,- 16+-hour days. As more community practices, academic centers, and hospitals align to share and leverage expertise in their efforts to form more streamlined, patient-centered delivery systems for cancer care, we need to set up, refine, and integrate pathways into pathway programs that will pave the way to the delivery of value-based care.
Click on the PDF icon at the top of this introduction to read the full article.
Oncology 2015: new therapies and new transitions toward value-based cancer care
The past year has been an exciting one for new oncology and hematology drug approvals and the continued evolution of our oncology delivery system toward high quality and value. In all, at press time in mid-November, the US Food and Drug Administration (FDA) had approved or granted expanded indications for 24 drugs, compared with 19 in the 2 preceding years. Of those 24 approvals, 7 were accelerated and 6 were expanded approvals, and 3 alone were for the immunotherapeutic drug, nivolumab – 2 for non-small-cell lung cancer (NSCLC) and 1 for metastatic melanoma.
Click on the PDF icon at the top of this introduction to read the full article.
The past year has been an exciting one for new oncology and hematology drug approvals and the continued evolution of our oncology delivery system toward high quality and value. In all, at press time in mid-November, the US Food and Drug Administration (FDA) had approved or granted expanded indications for 24 drugs, compared with 19 in the 2 preceding years. Of those 24 approvals, 7 were accelerated and 6 were expanded approvals, and 3 alone were for the immunotherapeutic drug, nivolumab – 2 for non-small-cell lung cancer (NSCLC) and 1 for metastatic melanoma.
Click on the PDF icon at the top of this introduction to read the full article.
The past year has been an exciting one for new oncology and hematology drug approvals and the continued evolution of our oncology delivery system toward high quality and value. In all, at press time in mid-November, the US Food and Drug Administration (FDA) had approved or granted expanded indications for 24 drugs, compared with 19 in the 2 preceding years. Of those 24 approvals, 7 were accelerated and 6 were expanded approvals, and 3 alone were for the immunotherapeutic drug, nivolumab – 2 for non-small-cell lung cancer (NSCLC) and 1 for metastatic melanoma.
Click on the PDF icon at the top of this introduction to read the full article.
Changing oncology compliance standards: step 1 in re-valuing clinician workload for value-based cancer care
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Click on the PDF icon at the top of this introduction to read the full article.
Pooling knowledge to tailor an integrated delivery system
What an exciting and challenging year 2014 has been! As it draws to a close, we also celebrate the first year of the merger between The Journal of Supportive Oncology and Community Oncology to form our current title, The Journal of Community and Supportive Oncology. We hope that by combining the clinical and supportive/palliative components of our specialty, we are able to serve as a vital forum and resource by providing you with a “one-stop shop” to support you in your practice of oncology.
Click on the PDF icon at the top of this introduction to read the full article.
What an exciting and challenging year 2014 has been! As it draws to a close, we also celebrate the first year of the merger between The Journal of Supportive Oncology and Community Oncology to form our current title, The Journal of Community and Supportive Oncology. We hope that by combining the clinical and supportive/palliative components of our specialty, we are able to serve as a vital forum and resource by providing you with a “one-stop shop” to support you in your practice of oncology.
Click on the PDF icon at the top of this introduction to read the full article.
What an exciting and challenging year 2014 has been! As it draws to a close, we also celebrate the first year of the merger between The Journal of Supportive Oncology and Community Oncology to form our current title, The Journal of Community and Supportive Oncology. We hope that by combining the clinical and supportive/palliative components of our specialty, we are able to serve as a vital forum and resource by providing you with a “one-stop shop” to support you in your practice of oncology.
Click on the PDF icon at the top of this introduction to read the full article.
Quality care is a team effort
Everyone in community oncology practice has a role to play in the delivery of quality care. If you are looking to implement a quality program, each member of the practice, patients included, should be involved in the planning, implementing, reporting, and revising processes. Once those processes are in place, the practice can set up partnerships with payers based on standardized measures, costs, and outcomes, with appropriate payments.
Click on the PDF icon at the top of this introduction to read the full article.
Everyone in community oncology practice has a role to play in the delivery of quality care. If you are looking to implement a quality program, each member of the practice, patients included, should be involved in the planning, implementing, reporting, and revising processes. Once those processes are in place, the practice can set up partnerships with payers based on standardized measures, costs, and outcomes, with appropriate payments.
Click on the PDF icon at the top of this introduction to read the full article.
Everyone in community oncology practice has a role to play in the delivery of quality care. If you are looking to implement a quality program, each member of the practice, patients included, should be involved in the planning, implementing, reporting, and revising processes. Once those processes are in place, the practice can set up partnerships with payers based on standardized measures, costs, and outcomes, with appropriate payments.
Click on the PDF icon at the top of this introduction to read the full article.